Viskase Holdings, Inc. (VISK): Cash & Equivalents
$42.57M
As of 2025-12-31
$7.91M
As of 2026-06-30
-3.2%
3-year compound annual growth
-2.4%
5-year compound annual growth
+13.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.57M | -9.1% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $46.86M | -0.3% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $47.01M | +0.1% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $46.98M | -1.4% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $47.64M | -1.0% | 2023-02-16, Balance as of period end |
| 2020-12-31 | $48.14M | +784.0% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $5.45M | -16.2% | 2021-02-23, Balance as of period end |
| 2018-12-31 | $6.50M | -13.1% | 2020-02-19, Balance as of period end |
| 2017-12-31 | $7.48M | -2.1% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $7.64M | -34.6% | 2018-03-21, Balance as of period end |
| 2015-12-31 | $11.67M | -66.2% | 2017-03-24, Balance as of period end |
| 2014-12-31 | $34.56M | +430.1% | 2016-03-21, Balance as of period end |
| 2013-12-31 | $6.52M | -91.6% | 2015-03-05, Balance as of period end |
| 2012-12-31 | $77.35M | -25.9% | 2014-03-14, Balance as of period end |
| 2011-12-31 | $104.32M | -73.8% | 2014-03-14, Balance as of period end |
| 2010-12-31 | $397.53M | +688.1% | 2013-03-18, Balance as of period end |
| 2009-12-31 | $50.44M | n/a | 2012-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | $42.57M | -9.1% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $18.60M | +22.6% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $36.81M | +47.2% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $28.69M | -59.9% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $46.30M | +23.2% |
Compare VISK, PMCB, CGTX, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗